Zai Lab Ltd. ADR (ZLAB) News

Zai Lab Ltd. ADR (ZLAB): $20.17

0.13 (+0.65%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ZLAB to Watchlist
Sign Up

Industry: China

Industry

B

Ranked

#32 of 40

in industry

Filter ZLAB News Items

ZLAB News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ZLAB News Highlights

  • For ZLAB, its 30 day story count is now at 5.
  • Over the past 15 days, the trend for ZLAB's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about ZLAB are LAB, DRUG and AC.

Latest ZLAB News From Around the Web

Below are the latest news stories about ZAI LAB LTD that investors may wish to consider to help them evaluate ZLAB as an investment opportunity.

What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock

Zai Lab Limited Unsponsored ADR (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Yahoo | December 22, 2023

Zai Lab Announces Participation in January Investor Conference

SHANGHAI & CAMBRIDGE, Mass., December 19, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conference in January 2024:

Yahoo | December 19, 2023

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for life-threatening diseases and other public health threats, today announced that China’s National Healthcare Security Administration (NHSA) has added the oral formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquired bacterial pneumonia (CABP) and ac

Yahoo | December 13, 2023

Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List

SHANGHAI & CAMBRIDGE, Mass., December 13, 2023--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2023 National Reimbursement Drug List (NRDL) released by China’s National Healthcare Security Administration (NHSA) has been updated to include the following medicines and indications:

Yahoo | December 13, 2023

Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 7, 2023

14 Best Short-Term Stocks to Invest In

In this article, we will take a look at 14 best short-term stocks to invest in. To skip our analysis of the recent market activity, you can go directly to see the 5 Best Short-Term Stocks to Invest In. Momentum investing is a key strategy used for short term investments, typically grouped in with other […]

Yahoo | November 23, 2023

Institutional investors may adopt severe steps after Zai Lab Limited's (NASDAQ:ZLAB) latest 6.3% drop adds to a year losses

Key Insights Institutions' substantial holdings in Zai Lab implies that they have significant influence over the...

Yahoo | November 17, 2023

Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript

Zai Lab Limited (NASDAQ:ZLAB) Q3 2023 Earnings Call Transcript November 8, 2023 Operator: Hello, ladies and gentlemen. Thank you for standing by, and welcome to Zai Lab’s Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at […]

Yahoo | November 9, 2023

Zai Lab Announces Third Quarter 2023 Financial Results and Recent Corporate Updates

Total product revenue of $69.2 million for the third quarter of 2023, representing 22% y-o-y growth; 27% y-o-y growth at constant exchange rate (CER)VYVGART® (efgartigimod alfa injection) achieved $4.9 million sales since its commercial launch in September in ChinaStrong balance sheet with a cash position of $822.2 million as of September 30, 2023, compared to $876.4 million as of June 30, 2023Company to host conference call and webcast on November 8, 2023, at 8:00 a.m. ET SHANGHAI, China and CA

Yahoo | November 7, 2023

Zai Lab Announces Participation in November Investor Conferences

SHANGHAI, China and CAMBRIDGE, Mass., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in November 2023: Jefferies London Healthcare ConferenceFireside Chat: Wednesday, November 15th at 1:00 p.m. GMTLocation: London 6th Annual Evercore ISI HealthCONx ConferenceFireside Chat: Wednesday, November 29th at 1:45 p.m. ESTLocation: Miami A live webcast

Yahoo | October 26, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!